Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma

被引:25
|
作者
Huang, Chun-Teng [1 ,2 ,4 ]
Liu, Chia-Jen [1 ,2 ]
Ko, Po-Shen [1 ,2 ]
Liu, Han-Tsung [1 ,2 ]
Yu, Yuan-Bin [1 ,2 ]
Hsiao, Liang-Tsai [1 ,2 ]
Gau, Jyh-Pyng [1 ,2 ]
Tzeng, Cheng-Hwai [1 ,2 ]
Chiou, Tzeon-Jye [2 ,3 ]
Liu, Jin-Hwang [1 ,2 ]
Yang, Muh-Hwa [2 ,6 ]
Huang, Ling-Ju [2 ,5 ]
Liu, Chun-Yu [2 ,6 ]
机构
[1] Taipei Vet Gen Hosp, Div Hematol & Oncol, Dept Med, Taipei, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Div Transfus Med, Dept Med, Taipei, Taiwan
[4] Taipei City Hosp, Div Hematol & Oncol, Dept Med, Yang Ming Branch, Taipei, Taiwan
[5] Taipei Vet Gen Hosp, Div Gen Med, Dept Med, 201,Sec 2,Shipai Rd, Taipei 11217, Taiwan
[6] Taipei Vet Gen Hosp, Div Med Oncol, Dept Oncol, Taipei, Taiwan
来源
BMC INFECTIOUS DISEASES | 2017年 / 17卷
关键词
Bloodstream infection; Multiple myeloma; Risk factor; ABSOLUTE LYMPHOCYTE COUNT; BACTERIAL-INFECTION; WORKING PARTY; COMPLICATIONS; BACTEREMIA; SURVIVAL; IMPACT;
D O I
10.1186/s12879-016-2155-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Patients with multiple myeloma are generally immune-compromised either due to pronounced depression in primary antibody responses or because of anti-myeloma therapy. Infection is a major risk factor for early deaths among these patients. The impact of blood stream infections (BSI) on newly diagnosed myeloma patients has been less studied. We aimed to study the incidence and risk factors of BSI within 3 months after diagnosis of multiple myeloma in a tertiary referral center. Methods: Between November 2002 and December 2008, consecutive patients with multiple myeloma in Taipei Veterans General Hospital were retrospectively enrolled. Characteristics of patients with or without BSI were collected. Possible factors associated with development of BSI were analyzed by Cox regression. Results: There were a total of 222 patients. The incidence of BSI within 3 months after diagnosis is 11.7%. The patients with BSI had poorer survival outcomes than those without (mortality rate: 50% vs. 20.9%, p < 0.001). Moreover, advanced International Staging System stage (stage III vs. I/II: odds ratio [OR] 2.69, p = 0.049) and poor Eastern Cooperative Oncology Group (ECOG) performance status (ECOG > 2 vs. <= 2: OR 3.58, p = 0.005) were the independent risk factors of BSI, whereas immunoglobulin deficiency and low absolute lymphocyte count were not associated with risk of BSI development. Conclusions: Our study highlights the characteristic of myeloma patients with BSI and the importance of disease and host factors on risk of BSI. Myeloma patients with risks of BSI should be properly managed to reduce early mortality.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] RISK OF EARLY SEVERE INFECTIONS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS TREATED WITH NOVEL AGENTS: A POOLED ANALYSIS
    Bonello, F.
    D'Agostino, M.
    Offidani, M.
    Petrucci, M. T.
    Liberati, A. M.
    Patriarca, F.
    Capra, A.
    Benevolo, G.
    Gaidano, G.
    Barila, G.
    Galli, M.
    Cascavilla, N.
    Aquino, S.
    Ballanti, S.
    Pietrantuono, G.
    Pulini, S.
    Derudas, D.
    De Fabritis, P.
    Corradini, P.
    Conticello, C.
    Cavo, M.
    Sonneveld, P.
    Boccadoro, M.
    Bringhen, S.
    HAEMATOLOGICA, 2021, 106 (10) : 11 - 11
  • [42] The Impact of Hyperglycemia on Risk of Severe Infections during Early Period of Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma
    Jung, Sung-Hoon
    Jang, Hee-Chang
    Lee, Seung-Shin
    Ahn, Jae-Sook
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [43] Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma
    Merz, Maximillan
    Salwender, Hans-Juergen
    Haenel, Mathias
    Bertsch, Uta
    Kunz, Christina
    Hielscher, Thomas
    Blau, Igor W.
    Scheid, Christof
    Mai, Elias Karl
    Hose, Dirk
    Schurich, Baerbel
    Munder, Markus
    Brossart, Peter
    Gerecke, Christian
    Lindemann, Hans Walter
    Zeis, Matthias
    Weisel, Katja C.
    Duerig, Jan
    Goldschmidt, Hartmut
    BLOOD, 2015, 126 (23)
  • [44] Peripheral neuropathy in newly diagnosed multiple myeloma patients
    Ballegaard, Martin
    Gimsing, Peter
    NEUROLOGY, 2008, 70 (11) : A366 - A367
  • [45] Review of 1027 patients with newly diagnosed multiple myeloma
    Kyle, RA
    Gertz, MA
    Witzig, TE
    Lust, JA
    Lacy, MQ
    Dispenzieri, A
    Fonseca, R
    Rajkumar, SV
    Offord, JR
    Larson, DR
    Plevak, ME
    Therneau, TM
    Greipp, PR
    MAYO CLINIC PROCEEDINGS, 2003, 78 (01) : 21 - 33
  • [46] Management of Newly Diagnosed Elderly Multiple Myeloma Patients
    Crystal Antoine-Pepeljugoski
    Marc Justin Braunstein
    Current Oncology Reports, 2019, 21
  • [47] Management of Newly Diagnosed Elderly Multiple Myeloma Patients
    Antoine-Pepeljugoski, Crystal
    Braunstein, Marc Justin
    CURRENT ONCOLOGY REPORTS, 2019, 21 (07)
  • [48] Frontline therapy for newly diagnosed patients with multiple myeloma
    Jung, Sung-Hoon
    Jo, Jae-Cheol
    Song, Ga-Young
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Ahn, Jae-Sook
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BLOOD RESEARCH, 2020, 55 : 37 - 42
  • [49] Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
    Hussain, Azhar
    Almenfi, Hana Farag
    Almehdewi, Abdelfattah M.
    Hamza, Mohammed S.
    Bhat, Malpe Surekha
    Vijayashankar, Narasimha Prasad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (05)
  • [50] Treatment for patients with newly diagnosed multiple myeloma in 2015
    Mateos, Maria-Victoria
    Ocio, Enrique M.
    Paiva, Bruno
    Rosinol, Laura
    Martinez-Lopez, Joaquin
    Blade, Joan
    Lahuerta, Juan-Jose
    Garcia-Sanz, Ramon
    San Miguel, Jesus F.
    BLOOD REVIEWS, 2015, 29 (06) : 387 - 403